Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 20/20 | 0.79 |
| ▸ | THRB | P10828 | 2/20 | 0.60 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL412009 | 0.95 | TGFBR1 (0.78) | TGFBR1THRBMAPK14 | |
| SCHEMBL412166 | 0.91 | TGFBR1 (0.65) | TGFBR1THRBMAPK14 | |
| SCHEMBL414261 | 0.91 | TGFBR1 (0.69) | TGFBR1THRBMAPK14 | |
| SCHEMBL413647 | 0.91 | TGFBR1 (0.82) | TGFBR1THRBMAPK14 | |
| SCHEMBL409123 | 0.90 | TGFBR1 (0.68) | TGFBR1THRBMAPK14 | |
| SCHEMBL410334 | 0.89 | TGFBR1 (0.82) | TGFBR1THRBMAPK14 | |
| SCHEMBL410876 | 0.89 | TGFBR1 (0.67) | TGFBR1THRBMAPK14 | |
| SCHEMBL413218 | 0.89 | TGFBR1 (0.71) | TGFBR1THRBMAPK14 | |
| SCHEMBL412459 | 0.89 | TGFBR1 (0.67) | TGFBR1THRBMAPK14 | |
| SCHEMBL409788 | 0.88 | TGFBR1 (0.70) | TGFBR1THRBMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040106604-A1 | Novel pyrrole derivatives as pharmaceutical agents | ELI LILLY AND COMPANY | 2004-06-03 | — | — | US | claimed |
| WO-2012138945-A1 | METHODS OF TREATING SCHIZOPHRENIA WITH PYRAZOLE DERIVATIVE INHIBITORS OF TGF - BETA | AESTUS THERAPEUTICS, INC. (US) | 2012-10-11 | — | — | WO | disclosed |
| US-20120021519-A1 | EFFICIENT INDUCTION OF PLURIPOTENT STEM CELLS USING SMALL MOLECULE COMPOUNDS | PRESIDENTS AND FELLOWS OF HARVARD COLLEGE (US) | 2012-01-26 | — | — | US | disclosed |
| US-7087626-B2 | Pyrrole derivatives as pharmaceutical agents | ELI LILLY AND COMPANY (US) | 2006-08-08 | — | — | US | disclosed |
| US-20040106604-A1 | Novel pyrrole derivatives as pharmaceutical agents | ELI LILLY AND COMPANY | 2004-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106604-A1 | Novel pyrrole derivatives as pharmaceutical agents | TGFBR1, SMAD3, TGFBR2 | TGFBR1 1/4885THRB 500/4885MAPK14 546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.